{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:03:48Z","timestamp":1787317428408,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"FWO","award":["12AQF24N"],"award-info":[{"award-number":["12AQF24N"]}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["fundamental clinical investigatorship"],"award-info":[{"award-number":["fundamental clinical investigatorship"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["Een Hart voor ALS"],"award-info":[{"award-number":["Een Hart voor ALS"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["Laeversfonds voor ALS Onderzoek"],"award-info":[{"award-number":["Laeversfonds voor ALS Onderzoek"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders","award":["E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders"],"award-info":[{"award-number":["E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders"]}]},{"name":"ALS Liga Belgi\u00eb","award":["ALS Liga Belgi\u00eb"],"award-info":[{"award-number":["ALS Liga Belgi\u00eb"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07696-z","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:57:28Z","timestamp":1766365048000},"page":"3437-3447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Support vector machine classification of 18F-FDG PET scans across subtypes of amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-208X","authenticated-orcid":false,"given":"Chunmeng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Foucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"\u00d6ijerstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouke","family":"Ombelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ingre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"De Vocht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"7696_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4\/ASSET\/EED00479-89A5-43FE-8787-77065C23ECD2\/MAIN.ASSETS\/GR4.JPG","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(17)31287-4\/ASSET\/EED00479-89A5-43FE-8787-77065C23ECD2\/MAIN.ASSETS\/GR4.JPG.","journal-title":"Lancet"},{"key":"7696_CR2","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ENE.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918\u201329. https:\/\/doi.org\/10.1111\/ENE.14393.","journal-title":"Eur J Neurol"},{"key":"7696_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.010.","journal-title":"Neuron"},{"key":"7696_CR4","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1212\/NXG.0000000000000670\/ASSET\/61659FF2-6425-490E-9B16-332C578CC6FB\/ASSETS","volume":"8","author":"S Breevoort","year":"2022","unstructured":"Breevoort S, Gibson S, Figueroa K, et al. Expanding clinical spectrum of C9ORF72 -Related disorders and promising therapeutic strategies: A review. Neurol Genet. 2022;8:e670. https:\/\/doi.org\/10.1212\/NXG.0000000000000670\/ASSET\/61659FF2-6425-490E-9B16-332C578CC6FB\/ASSETS\/GRAPHIC\/NXG.0000000000000670TU1.JPEG.","journal-title":"Neurol Genet"},{"key":"7696_CR5","doi-asserted-by":"publisher","unstructured":"van der Ende EL, Morenas-Rodriguez E, McMillan C, et al. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiol Aging. 2021;103. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2021.02.024. :158.e1-158.e5.","DOI":"10.1016\/J.NEUROBIOLAGING.2021.02.024"},{"key":"7696_CR6","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1212\/WNL.0000000000011093\/ASSET\/93BD4344-AB4D-4C9B-BD1B-7252A7CC295C\/ASSETS\/GRAPHIC\/18TTU1A.JPEG","volume":"96","author":"B Iazzolino","year":"2021","unstructured":"Iazzolino B, Peotta L, Zucchetti JP, et al. Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without C9orf72 mutation. Neurology. 2021;96:E141\u201352. https:\/\/doi.org\/10.1212\/WNL.0000000000011093\/ASSET\/93BD4344-AB4D-4C9B-BD1B-7252A7CC295C\/ASSETS\/GRAPHIC\/18TTU1A.JPEG.","journal-title":"Neurology"},{"key":"7696_CR7","doi-asserted-by":"publisher","first-page":"534481","DOI":"10.3389\/FNINS.2020.00316\/BIBTEX","volume":"14","author":"F Esselin","year":"2020","unstructured":"Esselin F, Mouzat K, Polge A, et al. Clinical phenotype and inheritance in patients with C9ORF72 hexanucleotide repeat expansion: results from a large French cohort. Front Neurosci. 2020;14:534481. https:\/\/doi.org\/10.3389\/FNINS.2020.00316\/BIBTEX.","journal-title":"Front Neurosci"},{"key":"7696_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/JAMANEUROL.2014.62","volume":"71","author":"K Laere","year":"2014","unstructured":"Laere K, Van, Vanhee A, Verschueren J, et al. Value of 18Fluorodeoxyglucose\u2013Positron-Emission tomography in amyotrophic lateral sclerosis: A prospective study. JAMA Neurol. 2014;71:553\u201361. https:\/\/doi.org\/10.1001\/JAMANEUROL.2014.62.","journal-title":"JAMA Neurol"},{"key":"7696_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1212\/WNL.0000000000000792\/SUPPL_FILE\/TABLE_E-2.DOC","volume":"83","author":"M Pagani","year":"2014","unstructured":"Pagani M, Chi\u00f2 A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067\u201374. https:\/\/doi.org\/10.1212\/WNL.0000000000000792\/SUPPL_FILE\/TABLE_E-2.DOC.","journal-title":"Neurology"},{"key":"7696_CR10","doi-asserted-by":"publisher","unstructured":"Foucher J, \u00d6ijerstedt L, Lovik A, et al. ECAS correlation with metabolic alterations on FDG-PET imaging in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25. https:\/\/doi.org\/10.1080\/21678421.2024.2361695.","DOI":"10.1080\/21678421.2024.2361695"},{"key":"7696_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.2967\/JNUMED.115.166272","volume":"57","author":"D Van Weehaeghe","year":"2016","unstructured":"Van Weehaeghe D, Ceccarini J, Delva A, et al. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016;57:1238\u201343. https:\/\/doi.org\/10.2967\/JNUMED.115.166272.","journal-title":"J Nucl Med"},{"key":"7696_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/CELLS12060933\/S1","volume":"12","author":"J De Vocht","year":"2023","unstructured":"De Vocht J, Van Weehaeghe D, Ombelet F, et al. Differences in cerebral glucose metabolism in ALS patients with and without C9orf72 and SOD1 mutations. Cells. 2023;12:933. https:\/\/doi.org\/10.3390\/CELLS12060933\/S1.","journal-title":"Cells"},{"key":"7696_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/S00259-013-2667-5\/FIGURES\/3","volume":"41","author":"A Cistaro","year":"2014","unstructured":"Cistaro A, Pagani M, Montuschi A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41:844\u201352. https:\/\/doi.org\/10.1007\/S00259-013-2667-5\/FIGURES\/3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41398-019-0381-1","volume":"9","author":"J Diehl-Schmid","year":"2019","unstructured":"Diehl-Schmid J, Licata A, Goldhardt O, et al. FDG-PET underscores the key role of the thalamus in frontotemporal Lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry. 2019;9:1\u201311. https:\/\/doi.org\/10.1038\/S41398-019-0381-1. ;SUBJMETA=2421,476,53,692,699;KWRD=DIAGNOSTIC+MARKERS,PSYCHIATRIC+DISORDERS.","journal-title":"Transl Psychiatry"},{"key":"7696_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/J.BIOPSYCH.2009.07.019","volume":"66","author":"D Sun","year":"2009","unstructured":"Sun D, van Erp TGM, Thompson PM, et al. Elucidating a magnetic resonance Imaging-Based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol Psychiatry. 2009;66:1055\u201360. https:\/\/doi.org\/10.1016\/J.BIOPSYCH.2009.07.019.","journal-title":"Biol Psychiatry"},{"key":"7696_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/S00259-022-05987-3\/TABLES\/2","volume":"50","author":"A Canosa","year":"2023","unstructured":"Canosa A, Martino A, Manera U, et al. Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2023;50:784\u201391. https:\/\/doi.org\/10.1007\/S00259-022-05987-3\/TABLES\/2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/S00259-018-4246-2\/FIGURES\/3","volume":"46","author":"A Sala","year":"2019","unstructured":"Sala A, Iaccarino L, Fania P, et al. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2019;46:1117\u201331. https:\/\/doi.org\/10.1007\/S00259-018-4246-2\/FIGURES\/3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/S00415-022-11445-9\/TABLES\/4","volume":"270","author":"A Canosa","year":"2023","unstructured":"Canosa A, Martino A, Giuliani A, et al. Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[18F]FDG-PET study. J Neurol. 2023;270:953\u20139. https:\/\/doi.org\/10.1007\/S00415-022-11445-9\/TABLES\/4.","journal-title":"J Neurol"},{"key":"7696_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3264-1","volume-title":"The nature of statistical learning theory","author":"VN Vapnik","year":"2000","unstructured":"Vapnik VN. The nature of statistical learning theory. New York, NY: Springer New York; 2000."},{"key":"7696_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-018-0458-5","volume":"8","author":"M Devrome","year":"2018","unstructured":"Devrome M, Van Weehaeghe D, De Vocht J, et al. Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Res. 2018;8:110. https:\/\/doi.org\/10.1186\/s13550-018-0458-5.","journal-title":"EJNMMI Res"},{"key":"7696_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/21678421.2018.1476548","volume":"19","author":"L D\u2019hulst","year":"2018","unstructured":"D\u2019hulst L, Van Weehaeghe D, Chi\u00f2 A, et al. Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:570\u20137. https:\/\/doi.org\/10.1080\/21678421.2018.1476548.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7696_CR22","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1007\/s00259-022-05808-7","volume":"49","author":"M Reinartz","year":"2022","unstructured":"Reinartz M, Luckett ES, Schaeverbeke J, et al. Classification of 18F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth. Eur J Nucl Med Mol Imaging. 2022;49:3772\u201386. https:\/\/doi.org\/10.1007\/s00259-022-05808-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR23","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s00259-020-04786-y","volume":"47","author":"D van Weehaeghe","year":"2020","unstructured":"van Weehaeghe D, Devrome M, Schramm G, et al. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur J Nucl Med Mol Imaging. 2020;47:2681\u201390. https:\/\/doi.org\/10.1007\/s00259-020-04786-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/S00259-011-1979-6\/FIGURES\/3","volume":"39","author":"A Cistaro","year":"2012","unstructured":"Cistaro A, Valentini MC, Chi\u00f2 A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: A FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251\u20139. https:\/\/doi.org\/10.1007\/S00259-011-1979-6\/FIGURES\/3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7696_CR25","doi-asserted-by":"publisher","unstructured":"Ferraro PM, Campi C, Miceli A, et al. 18F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches. Eur J Radiol Open. 2022;9. https:\/\/doi.org\/10.1016\/j.ejro.2022.100394.","DOI":"10.1016\/j.ejro.2022.100394"},{"key":"7696_CR26","doi-asserted-by":"publisher","first-page":"064301","DOI":"10.1118\/1.4800806","volume":"40","author":"A Rahmim","year":"2013","unstructured":"Rahmim A, Qi J, Sossi V. Resolution modeling in PET imaging: Theory, practice, benefits, and pitfalls. Med Phys. 2013;40:064301. https:\/\/doi.org\/10.1118\/1.4800806.","journal-title":"Med Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07696-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:06Z","timestamp":1774401966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07696-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7696"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07696-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PVD has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, VectorY, Zambon, Amylyx, Novartis, Prilenia, Verge Genomics, Sapreme Technologies, Trace Neuroscience, NRG Therapeutics (paid to the institution). PVD has received speaker fees from Biogen and Amylyx (paid to the institution).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}